IRLA
IRulya Therapeutics Inc.
IRLA | NASDAQ
$32.06
-$0.89 (-2.70%)
Nov 2, 2026, 1:38 PM ET · Market open
Company Profile
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Key Executives
| Name | Position |
|---|---|
| Brigette Roberts | CEO, Principal Executive Officer & Director |
| Dirk Thye | Chief Executive Officer, Chief Medical Officer & Director |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer |
| Keith Fandrick | Chief Operating Officer |
| Charles S. Ryan | President |
| Guenter R. Janhofer | Chief Scientific Officer |
| John C. Militello | CFO, Principal Financial Officer & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 3 | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 09, 2026 | 8-K | Current Report |
IRulya Therapeutics Inc.
IRLA
| Country | United States |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Brigette Roberts |
Stock Details
| Ticker Symbol | IRLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001662774 |
| CUSIP Number | 22053A305 |
| ISIN Number | US22053A3059 |
| SIC Code | 2836 |
Recent News
- 18 days ago / globenewswire.comIRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
- 24 days ago / globenewswire.comQuince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
- 27 days ago / seekingalpha.comQuince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
- 1 month ago / seekingalpha.comQuince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
- 2 months ago / globenewswire.comQuince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
- 2 months ago / globenewswire.comQuince Therapeutics to Participate in September 2026 Investor Conferences
- 3 months ago / globenewswire.comQuince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Add to Watchlist
Select watchlists to add or remove IRLA